Core Viewpoint - Investors are expressing concerns about the declining stock price of Wantai Biological Pharmacy Enterprise (万泰生物), questioning why the core assets of Yangshengtang (养生堂) are not injected into Wantai to boost its stock price [2]. Group 1: Company Strategy - Wantai Biological has clarified its business focus, stating that it engages in the research and industrialization of products aimed at disease diagnosis and prevention, while Yangshengtang focuses on products for disease treatment [2]. - The company emphasizes its commitment to the field of in vitro diagnostic reagents and preventive products, distinguishing its operations from those of Yangshengtang, which is involved in therapeutic innovative drugs [2]. - There is a possibility that Wantai Biological may explore the inclusion of the therapeutic segment into the listed company at an appropriate time in the future [2].